Treace Medical Concepts, Inc.
NASDAQ:TMCIMedical - Devices
+$0.08 today
- Market cap
- $296.98M
- Beta
- 1.41
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$0.95
Volume 0.18M
Average 0.73M
TMCI Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Treace Medical Concepts, Inc.NASDAQ: TMCI
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 28.6% from a year ago
Cash & equivalents stood at $9.54M at the end of Q1 FY2026, down 28.6% from a year earlier and down 10.9% from the prior quarter. Over 3 fiscal years it compounded at -18.1% a year.
Context
- Cash & equivalents amounted to 5.2% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
- Cash & equivalents increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -28.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 10.71M USD
- Year-over-year change
- -5.7%
- 4-year CAGR
- -43.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.71M | -5.7% |
| FY2024 | 2024-12-31 | 11.35M | -12.6% |
| FY2023 | 2023-12-31 | 12.98M | -33.3% |
| FY2022 | 2022-12-31 | 19.47M | -81.6% |
| FY2021 | 2021-12-31 | 105.83M | — |
Cash & Equivalents vs competitors
How TMCI compares with its peers on the latest reported figures
- TMCI's Mar 2026 cash & equivalents of $9.54M is the lowest of the 8 companies compared; the peer median is $35.85M.
- Its year-over-year change of -28.6% is the 5th highest of 8, against a peer median of -26.7%.
- Cash & equivalents amounts to 5.2% of total assets for TMCI, versus a peer median of 18.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $265.77M | +76.1% | +13.3% | 41.6% | |
| Mar 2026 | $49.79M | -26.7% | -0.1% | 22.6% | |
CBLLCeriBell, Inc. | Mar 2026 | $45.25M | -70.5% | -16.0% | 25.4% |
| Mar 2026 | $35.85M | +57.2% | +19.3% | 5.5% | |
| Mar 2026 | $30.28M | -23.8% | +33.8% | 18.0% | |
| Mar 2026 | $17.57M | -37.2% | +19.0% | 5.8% | |
| Mar 2026 | $14.25M | -57.4% | +29.6% | 2.8% | |
| Mar 2026 | $9.54M | -28.6% | -18.1% | 5.2% | |
| Peer median (excluding TMCI) | $35.85M | -26.7% | +19.0% | 18.0% | |
Competitors are the stored peer set for TMCI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 105.83M | 19.47M | 12.98M | 11.35M | 10.71M |
| Short-term Investments | 0 | 61.78M | 110.22M | 64.33M | 37.66M |
| Net Receivables | 18.57M | 29.2M | 38.06M | 40.8M | 42.16M |
| Inventory | 10.56M | 19.33M | 29.25M | 39.26M | 36.03M |
| Other Current Assets | 0 | 3.62M | 7.85M | 5.67M | 5.5M |
| Total Current Assets | 137.97M | 133.4M | 198.36M | 161.4M | 132.05M |
| Property, Plant & Equipment (Net) | 2.85M | 25.48M | 31.56M | 34.4M | 37.37M |
| Goodwill | 0 | 0 | 12.82M | 12.82M | 12.82M |
| Intangible Assets | 0 | 0 | 9.03M | 8.08M | 7.13M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 146K | 146K | 407K | 1.22M |
| Total Non-current Assets | 2.85M | 25.62M | 53.55M | 55.69M | 58.53M |
| Total Assets | 140.82M | 159.02M | 251.91M | 217.09M | 190.58M |
| Account Payables | 4.06M | 8.67M | 11.84M | 10.52M | 6.73M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.46M | 7.67M | 24.25M | 2.22M | 23.91M |
| Total Current Liabilities | 18.21M | 30.25M | 45.03M | 34.93M | 30.64M |
| Long-term Debt | 29.37M | 52.71M | 53.01M | 53.31M | 13.98M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 173K | 0 | 37K | 37K | 58.63M |
| Total Non-current Liabilities | 29.54M | 68.25M | 68.94M | 69.28M | 72.61M |
| Total Liabilities | 47.75M | 98.5M | 113.97M | 104.2M | 103.25M |
| Common Stock | 45K | 55K | 62K | 62K | 64K |
| Retained Earnings | (41.91M) | (84.72M) | (134.25M) | (189.99M) | (248.99M) |
| Accumulated OCI | 0 | (27K) | 163K | 97K | 72K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 93.07M | 60.53M | 137.94M | 112.89M | 87.33M |
| Total Debt | 29.37M | 68.59M | 70.3M | 69.65M | 13.98M |
| Net Debt | (76.47M) | 49.12M | 57.32M | 58.3M | 3.27M |
Treace Medical Concepts, Inc.
NASDAQ:TMCI
Intrinsic Alpha fair value
Locked
Current Price
$4.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.